CAMBRIDGE, Mass. / Apr 09, 2024 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed... Read More

CAMBRIDGE, Mass. / Apr 02, 2024 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of a restricted stock unit (RSU) award for 8,400 shares of Syros common stock to one newly hired employee in connection with commencing employment with Syros. This RSU was granted as a... Read More

Completed Enrollment of 190 Patients for Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial; Pivotal CR Data Expected by Mid-4Q 2024 Additional Data from SELECT-AML-1 Phase 2 Trial Also Expected in 2024 Completed a $45.0 Million Equity Offering, Extending Cash Runway into 2Q 2025 Management to Host Conference Call at 8:30 AM ET Today CAMBRIDGE, Mass. / Mar 27, 2024 / Business Wire / Syros Pharmaceuticals (NASDAQ: SYRS),... Read More

On track to report pivotal complete response data by mid-4Q 2024 CAMBRIDGE, Mass. / Mar 25, 2024 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the enrollment of 190 patients has been completed in the SELECT-MDS-1 Phase 3 clinical trial evaluating tamibarotene in newly... Read More

CAMBRIDGE, Mass. / Mar 20, 2024 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, March 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.... Read More

CAMBRIDGE, Mass. / Feb 27, 2024 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Conley Chee, will participate in a panel discussion at the TD Cowen 44 th Annual Health Care Conference. Management will also be available for one-on-one... Read More

On-Track to Complete Enrollment of 190 patients for Primary Analysis in SELECT-MDS-1 Phase 3 Trial in 1Q 2024; Pivotal CR Data Expected by Mid-4Q 2024 Additional Data from SELECT-AML-1 Phase 2 Trial Expected in 2024; Initial Data Demonstrated 100% CR/CRi Rate and Favorable Tolerability Profile Strengthened Balance Sheet with Gross Proceeds of Approximately $45.0 Million from Recent Equity Financing, Extending Cash Runway... Read More

CAMBRIDGE, Mass. / Dec 19, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced today that it has priced an underwritten offering of 4,939,591 shares of common stock at an offering price of $4.42 per share, and, in lieu of common stock to investors who so choose, pre-funded... Read More

100% CR/CRi Rate in Patients Treated with Tamibarotene, Venetoclax and Azacitidine Compared to 70% in Patients Randomized to Treatment with Venetoclax and Azacitidine Alone Triplet Regimen Continues to Demonstrate Favorable Tolerability Additional Data Expected in 2024 Management to Host Conference Call at 8:30 a.m. ET Today CAMBRIDGE, Mass. / Dec 06, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ: SYRS), a... Read More

CAMBRIDGE, Mass. / Nov 21, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences. Management will also be available for one-on-one meetings. Details are as follows: Piper Sandler... Read More

On track to report initial data from approximately 20 patients in SELECT-AML-1 trial in early December 2023 Expect to report pivotal CR data from SELECT-MDS-1 by mid-4Q 2024 Founding CEO, Nancy Simonian, M.D. to retire as CEO effective December 1, 2023; Conley Chee, CCO and CBO, to succeed as CEO Management to host a conference call at 8:30 a.m. ET today CAMBRIDGE, Mass. / Nov 14, 2023 / Business Wire / Syros Pharmaceuticals... Read More

CAMBRIDGE, Mass. / Nov 07, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 14, 2023 to report its third quarter 2023 financial results and provide a corporate update. To access the... Read More

Conley Chee, CCO and CBO, to succeed Nancy Simonian, M.D. as CEO; Dr. Simonian to retire as CEO, effective December 1, 2023, and will remain on the Board of Directors Planned workforce reduction of approximately 35% sharpens focus of organization on late-stage development of tamibarotene in MDS and AML and ongoing pre-launch activities CAMBRIDGE, Mass. / Oct 02, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a... Read More

CAMBRIDGE, Mass. / Sep 07, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 20,650 shares of Syros common stock to two newly hired employees in connection with commencing employment with Syros. These... Read More

On track to announce initial randomized data from SELECT-AML-1 trial in 4Q 2023 Expect to complete enrollment of 190 patients in SELECT-MDS-1 trial in 4Q 2023; pivotal CR data expected in 3Q 2024 Management to host a conference call at 8:30 a.m. ET today CAMBRIDGE, Mass. / Aug 08, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the... Read More

CAMBRIDGE, Mass. / Aug 04, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 16,050 shares of Syros common stock to two newly hired employees in connection with commencing employment with Syros. These... Read More

CAMBRIDGE, Mass. / Aug 01, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, August 8, 2023 to report its second quarter 2023 financial results and provide a corporate update. To access the... Read More

CAMBRIDGE, Mass. / Jul 05, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of a restricted stock unit (RSU) award for 9,000 shares of Syros common stock to one newly hired employee in connection with commencing employment with Syros. This RSU was granted as a... Read More

CAMBRIDGE, Mass. / Jun 08, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the Sidoti June 2023 Virtual Small-Cap Conference. Management will also be available for one-on-one... Read More

CAMBRIDGE, Mass. / Jun 01, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 29,250 shares of Syros common stock to three newly hired employees in connection with commencing employment with Syros. These... Read More

New data support further evaluation of SY-5609 for PDAC and HR+ breast cancer and demonstrate significant potential for SY-5609 in a wide range of tumor types and combinations Consistent with prior guidance, exploring partnership opportunities to advance development of SY-5609 CAMBRIDGE, Mass. / May 25, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new... Read More

On track to complete enrollment of 190 patients in 4Q 2023, with pivotal complete response (CR) data from SELECT-MDS-1 expected in 3Q 2024 Amended SELECT-MDS-1 study to add overall survival as key secondary endpoint Initial data from the randomized portion of SELECT-AML-1 trial expected in 4Q 2023 Management to host conference call at 8:30 a.m. ET today CAMBRIDGE, Mass. / May 10, 2023 / Business Wire / Syros Pharmaceuticals... Read More

CAMBRIDGE, Mass. / May 09, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities 2023 Life Sciences Conference. Management will also be available for one-on-one... Read More

CAMBRIDGE, Mass. / May 03, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 10, 2023 to report its first quarter 2023 financial results and provide a corporate update. To access the... Read More

CAMBRIDGE, Mass. / May 02, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 17,800 shares of Syros common stock to two newly hired employees in connection with commencing employment with Syros. These... Read More

CAMBRIDGE, Mass. / Mar 02, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter and full-year ended December 31, 2022 and provided a corporate update. “In 2022, we advanced our efforts to develop new standards of care for the frontline... Read More

CAMBRIDGE, Mass. / Feb 28, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming investor conferences in March. Management will also... Read More

CAMBRIDGE, Mass. / Feb 23, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full year 2022 financial results and provide a corporate update.... Read More

CAMBRIDGE, Mass. / Feb 09, 2023 / Business Wire / Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 12,400 shares of Syros common stock to two newly hired employees in connection with their commencement of employment with... Read More

Currently evaluating tamibarotene in combination with azacitidine pivotal SELECT-MDS-1 Phase 3 clinical trial in newly diagnosed HR-MDS patients with RARA gene overexpression CAMBRIDGE, Mass. / Jan 26, 2023 / Business Wire / -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the... Read More

Expect to Complete Enrollment in SELECT-MDS-1 Phase 3 Trial in 4Q 2023; Data Expected in 3Q 2024 On Track to Initiate Randomized Portion of SELECT-AML-1 Phase 2 Trial in 1Q 2023; Initial Data Expected 4Q 2023 Entering 2023 in Strong Financial Position, with Cash into 2Q 2025 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided... Read More

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 14,200 shares of Syros common stock to four newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing... Read More

Combination of tamibarotene and azacitidine in a Phase 2 trial demonstrated a high complete response rate, with rapid onset and clinically meaningful durability in newly diagnosed unfit acute myeloid leukemia (AML) patients with RARA overexpression Targeting RARA overexpression with tamibarotene is a novel targeted approach in newly diagnosed AML and MDS patients with potential to provide new frontline standards-of-care... Read More

83% composite complete response rate in newly diagnosed unfit AML patients with RARA gene overexpression Initial safety and clinical activity profile of the triplet regimen supports advancing SELECT-AML-1 into the randomized portion Management to host conference call at 12:00 p.m. ET today CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the... Read More